AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20630169 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Labeling Education
Number of subjects: 47
Study 20630169 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic Food Movement
Number of subjects: 47
Study 16914369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 36
Study 16914369 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 36
Study 16301878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (moderate dose, 50% above seizure threshold; n = 15)
Number of subjects: 45
Study 16301878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitemporal ECT (low dose, just above seizure threshold; n = 15)
Number of subjects: 45
Study 16301878 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral ECT (high dose, 400% above seizure threshold; n = 15)
Number of subjects: 45
Study 12173784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg (loading dose)
Number of subjects: 32
Study 12173784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg
Number of subjects: 32
Study 12173784 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 32
Study 12173784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 32
Study 9528867 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral computed tomographic pulmonary angiography (SCTA)
Number of subjects: 78
Study 9528867 — intervention group
Group type: COMPARATOR
Intervention: Lung ventilation‐perfusion scintigraphy (VQS)
Number of subjects: 78
Study 9528867 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTA
Number of subjects: 78
Study 9528867 — intervention group
Group type: COMPARATOR
Intervention: VQS
Number of subjects: 78
Study 8846800 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 8846800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2496993 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin and placebo
Number of subjects: 396
Study 2496993 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin and amikacin
Number of subjects: 396
Study 29680845 — intervention group
Group type: EXPERIMENTAL
Intervention: arthrocentesis plus methylprednisolone acetate
Number of subjects: 44
Study 29680845 — intervention group
Group type: EXPERIMENTAL
Intervention: arthrocentesis plus sodium hyaluronate
Number of subjects: 44
Study 29680845 — intervention group
Group type: EXPERIMENTAL
Intervention: arthrocentesis plus tenoxicam
Number of subjects: 44
Study 29680845 — intervention group
Group type: COMPARATOR
Intervention: arthrocentesis alone
Number of subjects: 44
Study 27473164 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered progressive resistance exercise
Number of subjects: 130
Study 27473164 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 130
Study 25633200 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied once every other day
Number of subjects: 54
Study 25633200 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate eye drops applied thrice daily
Number of subjects: 54
Study 24237006 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 950
Study 24237006 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 950
Study 20484090 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid alone
Number of subjects: 665
Study 20484090 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid plus personalized risk assessment
Number of subjects: 665
Study 20484090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 665
Study 18637604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg.kg(‐1)
Number of subjects: 20
Study 18637604 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg
Number of subjects: 20
Study 16767526 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20-mug subcutaneous, once daily)
Number of subjects: 60
Study 16767526 — intervention group
Group type: COMPARATOR
Intervention: Antiresorptive treatment (control group)
Number of subjects: 60
Study 14633528 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with ropivacaine 0.2%
Number of subjects: 48
Study 14633528 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion analgesia (CEA) with ropivacaine 0.2%
Number of subjects: 48
Study 14633528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCEA and CEA
Number of subjects: 48
Study 14633528 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 48
Study 14633528 — intervention group
Group type: COMPARATOR
Intervention: CEA
Number of subjects: 48
Study 14633528 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA and CEA
Number of subjects: 48
Study 11104317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (medication plus behavioral treatment)
Number of subjects: 579
Study 11104317 — intervention group
Group type: COMPARATOR
Intervention: Behavioral treatment alone
Number of subjects: 579
Study 11104317 — intervention group
Group type: COMPARATOR
Intervention: Regular community care
Number of subjects: 579
Study 9116551 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription for antibiotics for 10 days (group 1, 246 patients)
Number of subjects: 716
Study 9116551 — intervention group
Group type: COMPARATOR
Intervention: No prescription (group 2, 230 patients)
Number of subjects: 716
Study 9116551 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription for antibiotics if symptoms were not starting to settle after three days (group 3, 238 patients)
Number of subjects: 716
Study 8443450 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified self-tonometer with acoustic control signal and modified fixation lamp
Number of subjects: 30
Study 8443450 — intervention group
Group type: COMPARATOR
Intervention: Existing self-tonometer
Number of subjects: 30
Study 8443450 — intervention group
Group type: COMPARATOR
Intervention: Draeger hand-held applanation tonometer
Number of subjects: 30
Study 3528969 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC regimen
Number of subjects: 239
Study 3528969 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC regimen
Number of subjects: 239
Study 30463611 — intervention group
Group type: EXPERIMENTAL
Intervention: cALND (complementary axillary lymph node dissection)
Number of subjects: 963
Study 30463611 — intervention group
Group type: COMPARATOR
Intervention: SLNB (sentinel lymph node biopsy) alone
Number of subjects: 963
Study 30463611 — intervention group
Group type: EXPERIMENTAL
Intervention: cALND (with chemotherapy)
Number of subjects: 963
Study 30463611 — intervention group
Group type: EXPERIMENTAL
Intervention: cALND (before chemotherapy)
Number of subjects: 963
Study 30463611 — intervention group
Group type: EXPERIMENTAL
Intervention: cALND (without chemotherapy)
Number of subjects: 963
Study 30463611 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 963
Study 30463611 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 963
Study 30463611 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole breast or chest wall irradiation
Number of subjects: 963
Study 27406786 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A (100 units total; 20 units into parotid and 30 units into submandibular glands)
Number of subjects: 10
Study 27406786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 27406786 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (various studies included in meta-analysis)
Number of subjects: 10
Study 24837977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory adaptation (AA)
Number of subjects: 53
Study 24837977 — intervention group
Group type: COMPARATOR
Intervention: Hospital adaptation (HA)
Number of subjects: 53
Study 22767164 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized prolate ablation (OPA)
Number of subjects: 37
Study 22767164 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 37
Study 18755817 — intervention group
Group type: EXPERIMENTAL
Intervention: Talnetant 200 mg
Number of subjects: 12
Study 18755817 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 3 mg
Number of subjects: 12
Study 18755817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18487215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline (800 mg/day)
Number of subjects: 98
Study 18487215 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 98
Study 16864839 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotonic dystrophy type 1 (DM1)
Number of subjects: 42
Study 16864839 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotonic dystrophy type 2 (DM2)
Number of subjects: 42
Study 16864839 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study 12482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (20 and 40 ng.kg(‐1).min(‐1) for 15 min/dose)
Number of subjects: 36
Study 12482765 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (100 mg/day for 5 days)
Number of subjects: 36
Study 10683349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (initial 50 mg daily dose uptitrated to 100 mg after 1 month, continued up to 3 years)
Number of subjects: 2590
Study 10683349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (as adjunct to usual therapy)
Number of subjects: 2590
Study 10683349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 2590
Study 10683349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil with antiarrhythmics (class I or III, including amiodarone)
Number of subjects: 2590
Study 10683349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil and placebo (substudies)
Number of subjects: 2590
Study 9332510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg
Number of subjects: 39
Study 9332510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 800 mg
Number of subjects: 39
Study 9332510 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior antifungal therapy failed
Number of subjects: 39
Study 9332510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400-800 mg)
Number of subjects: 39
Study 11067180 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention program in schools, with parents and community-at-large for 3 years.
Number of subjects: 20
Study 11067180 — intervention group
Group type: COMPARATOR
Intervention: Delayed Program condition (control group).
Number of subjects: 20
Study 2944386 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, 1300 mg
Number of subjects: 100
Study 2944386 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate, 100 mg
Number of subjects: 100
Study 2944386 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate, 200 mg
Number of subjects: 100
Study 2944386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 31420895 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 150
Study 31420895 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 150
Study 31421686 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscosupplementation (VS) treatment
Number of subjects: 166
Study 31421686 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder patients
Number of subjects: 166
Study 27923279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 304
Study 27923279 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 304
Study 27923279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 304
Study 27923279 — intervention group
Group type: COMPARATOR
Intervention: Control (diet only)
Number of subjects: 304
Study 26201224 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mouth SRP + Roxithromycin (RXM)
Number of subjects: 70
Study 26201224 — intervention group
Group type: COMPARATOR
Intervention: SRP + Placebo
Number of subjects: 70
Study 24200619 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg administered in the morning
Number of subjects: 26
Study 24200619 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg administered in the evening
Number of subjects: 26
Study 24200619 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 mcg (morning or evening)
Number of subjects: 26
Study 24200619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22367374 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient cream containing 0.25% zinc pyrithione
Number of subjects: 60
Study 22367374 — intervention group
Group type: COMPARATOR
Intervention: Emollient cream alone
Number of subjects: 60
Study 19780002 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam
Number of subjects: 40
Study 19780002 — intervention group
Group type: COMPARATOR
Intervention: 50 mg tramadol
Number of subjects: 40
Study 19780002 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue analgesic (1 mg.kg(‐1) im meperidine)
Number of subjects: 40
Study 19780002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea-vomiting, bleeding, postoperative hemorrhage
Number of subjects: 40
Study 17058027 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation plus TACE and PVC (Group C)
Number of subjects: 112
Study 17058027 — intervention group
Group type: COMPARATOR
Intervention: Operation only (Group A)
Number of subjects: 112
Study 17058027 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation plus TACE (Group B)
Number of subjects: 112
Study 15517154 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg
Number of subjects: 9
Study 11318005 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 1 part per million in the supine position
Number of subjects: 16
Study 11318005 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 16
Study 11318005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of INO and prone positioning
Number of subjects: 16
Study 11318005 — intervention group
Group type: COMPARATOR
Intervention: INO in the supine position
Number of subjects: 16
Study 11318005 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning plus INO
Number of subjects: 16
Study 11318005 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation in the supine position
Number of subjects: 16
Study 9205222 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera-based method for calculating Tc-99m MAG3 clearance
Number of subjects: 49
Study 8486508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate as prophylactic migraine therapy
Number of subjects: 12
Study 8486508 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study 3468819 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 0
Study 3468819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29980595 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4822
Study 29980595 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4822
Study 27492532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg add-on to ICS plus LABA
Number of subjects: 912
Study 27492532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study 24947045 — intervention group
Group type: EXPERIMENTAL
Intervention: 5As Team (5AsT) intervention group
Number of subjects: 0
Study 24947045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24947045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level outcomes
Number of subjects: 0
Study 22104390 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection added to standard treatment (eccentric-loading exercises) for 12 weeks
Number of subjects: 33
Study 22104390 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (eccentric-loading exercises) alone for 12 weeks
Number of subjects: 33
Study 20815273 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenxiong Bushen Capsule (5 tablets, thrice a day)
Number of subjects: 70
Study 20815273 — intervention group
Group type: COMPARATOR
Intervention: Piracetam (5 tablets, twice a day)
Number of subjects: 70
Study 20815273 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenxiong Bushen Capsule
Number of subjects: 70
Study 20815273 — intervention group
Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 70
Study 20815273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 18560214 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 603
Study 18560214 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 603
Study 15804320 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument
Number of subjects: 0
Study 12445035 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 120 mg day‐1 for 7 days
Number of subjects: 12
Study 10602832 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school programs
Number of subjects: 0
Study 10602832 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school programs at work sites
Number of subjects: 0
Study 10602832 — intervention group
Group type: EXPERIMENTAL
Intervention: Back schools with intensive training
Number of subjects: 0
Study 7813261 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical radiologists and study radiologists measuring mediastinal lymph node size in CT scans.
Number of subjects: 60
Study 1950483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (NSAID)
Number of subjects: 100
Study 1950483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7274202 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc ammonium sulfate aerosol at a nominal concentration of 20 μg/m3
Number of subjects: 40
Study 7274202 — intervention group
Group type: COMPARATOR
Intervention: Control: Sodium chloride aerosol at a nominal concentration of 300 μg/m3
Number of subjects: 40
Study 31186401 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 0
Study 31186401 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no compound
Number of subjects: 0
Study 31186401 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30593763 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed fixation combined with vacuum‐assisted closure
Number of subjects: 53
Study 30593763 — intervention group
Group type: COMPARATOR
Intervention: Only reimplanted and sewn
Number of subjects: 53
Study 26723272 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized outpatient physiotherapy programme (Bleton technique)
Number of subjects: 110
Study 26723272 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy advice for neck problems
Number of subjects: 110
Study 26723272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Specialized and Standard physiotherapy)
Number of subjects: 110
Study 24496083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported prevalent diabetes
Number of subjects: 732
Study 24496083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported incident diabetes
Number of subjects: 732
Study 24496083 — intervention group
Group type: COMPARATOR
Intervention: No self-reported diabetes
Number of subjects: 732
Study 24496083 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims algorithm in fee-for-service Medicare participants
Number of subjects: 732
Study 22695310 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg vaginal natural progesterone
Number of subjects: 313
Study 22695310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 20064284 — intervention group
Group type: EXPERIMENTAL
Intervention: UMF 20+ honey (20 g)
Number of subjects: 20
Study 20064284 — intervention group
Group type: COMPARATOR
Intervention: Multiflora honey (20 g)
Number of subjects: 20
Study 17378904 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberogast (1.1 mL)
Number of subjects: 29
Study 17378904 — intervention group
Group type: COMPARATOR
Intervention: Control (1.1 mL)
Number of subjects: 29
Study 16344226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine myocardial SPECT using technetium 99m sestamibi
Number of subjects: 50
Study 12439764 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (c.c.HRT) with 1 mg estradiol plus 0.5 mg norethisterone acetate (NETA)
Number of subjects: 3917
Study 10450296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 459
Study 10450296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 459
Study 10450296 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study 7547823 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg elemental Calcium
Number of subjects: 84
Study 7547823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 2201403 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-mismatched platelets (MMG)
Number of subjects: 43
Study 2201403 — intervention group
Group type: COMPARATOR
Intervention: ABO-matched platelets (OG)
Number of subjects: 43
Study 6996139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of diazepam plus local anaesthetic spray
Number of subjects: 50
Study 6996139 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (methohexital plus succinylcholine)
Number of subjects: 50
Study 30870159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg bolus followed by continuous infusion (48 μg · kg · min for the first hour, 24 μg · kg · min for the second hour, and 10 μg · kg · min for the next 46 hours)
Number of subjects: 478